GlassScriptPhysician profile
Sharon D Crum
NPI 1174544563
$895.03
in general payments reported to CMS, 2019-2025
15 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $246 · 2023: $75.50 · 2024: $16.06 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $310.15 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Pfizer INC. | $88.49 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $82.74 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $44.89 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.27 | 2022-2023 | Farxiga |
| Amgen INC. | $41.43 | 2022-2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.47 | 2023 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.16 | 2021-2022 | |
| Melinta Therapeutics, LLC | $20.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2021 | |
| Urgo Medical North America, LLC | $16.06 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Janssen Pharmaceuticals, INC | $15.57 | 2021 | |
| Chiesi USA, INC. | $13.57 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Crum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.